Specialty: Primary Care, Primary sub-specialty: Respiratory disorders
Conditions
Interventions
All participants in the study will complete questionnaire measures about their asthma, quality of life and mindfulness. These will primarily be delivered online at baseline, 6 weeks (post baseline) an
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult (18 years or over) 2. Have a confirmed diagnosis of asthma- between steps 2 and 4 of BTS Asthma Guidelines for symptom severity (mild to moderate) 3. Have access to the Internet- which can be either a computer or a mobile device
Exclusion criteria
Exclusion criteria: 1. Under 18 years of age 2. Previously diagnosed major and unstable comorbid psychological disorders other than anxiety / depression (measured using the MINI neuropsychiatric interview questionnaire) 3. Current participation in another asthma intervention study 4. Have had acute exacerbation of asthma (needing a course of oral steroid or increased dose of maintenance steroid) within 28 days of the first intervention of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility outcomes: 1. Response rate is recorded as the number of participants who respond favourably to the Patient Invite Letter by 6 months 2. Recruitment rate is recorded as the number of eligible participants who consent to participate in the study by 6-9 months 3. Retention rate is recorded as the number of participants who consent to participate that remain in the study until the end of follow up at 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Headspace usage will measured by data access granted by Headspace to allow the study team to monitor intervention usage- and whether this is associated with symptom improvement which will be measured by using validated quality of life questionnaires, primarily the Asthma Quality of Life Questionnaire (AQLQ) at baseline, 6 weeks and 3 months 2. Participant experience of taking part in the study and the acceptability of the intervention will be measured by qualitative analysis of telephone interviews on a purposive sample of participants from the intervention group up to 6 weeks post- intervention 3. Anxiety and asthma- specific quality of life will be measured using validated questionnaire measures at baseline, 6 weeks and 3 months with the primary questionnaire outcome measure being the Asthma Quality of Life Questionnaire (AQLQ) 4. Self- reported mindfulness will be measured using validated questionnaire measures below at baseline, 6 weeks and 3 months 5. Asthma-related quality of life is measured by the Asthma Quality of Life Questionnaire (AQLQ) at baseline, 6 weeks and 3 months 6. Asthma control is measured by the Asthma Control Questionnaire (ACQ) at baseline, 6 weeks and 3 months 7. Anxiety and depression is measured by the Hospital Anxiety and Depression Scale (HADS) at baseline, 6 weeks and 3 months 8. Enablement is measured by the Patient Enablement Instrument (PEI) at baseline, 6 weeks and 3 months 9. Mindfulness is measured by the Philadelphia Mindfulness Scale (PMS) at baseline, 6 weeks and 3 months 10. Medication adherence is measured by the Medication Adherence Report Scale for Asthma (MARS-A) at baseline, 6 weeks and 3 months 11. Acceptance and action is measured by the Acceptance and action questionnaire (AAQ-II) at baseline, 6 weeks and 3 months | — |
Countries
England, United Kingdom
Contacts
Public ContactBen Ainsworth
Outcome results
None listed